Clinical trials: Post-transplant Hepatitis C
Hepatitis C
Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
The aim of the study is to assess whether patients with recurrent hepatitis C after liver transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment for 48 weeks.
- Trial name
- NCT00466219
- Testing
- Ribavirin, Pegylated interferon alpha2a
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Hepatitis C, Renal Insufficiency, Chronic
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated…
- Conditions
- Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
- Trial name
- NCT02902120
- Testing
- Post-transplant Grazoprevir and Elbasvir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Chronic Hepatitis c, Liver Transplant Infection
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable.
- Conditions
- Chronic Hepatitis c, Liver Transplant Infection, Kidney Transplant Infection
- Trial name
- NCT03723824
- Testing
- grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
- Where
- 2 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taichung Veterans General Hospital
Recurrent Hepatitis C
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
- Trial name
- REVERT (NCT00582738)
- Testing
- CsA-TAC (standard Treatment), Everolimus
- Where
- Argentina
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
HCV Infection, Liver Transplantation
MMF Influence on HCV Viral Evolution After Liver Transplantation
Samples from a large clinical trial comparing three immunosuppression regimens, two of which contained MMF, are used to identify the HCV viral quasispecies behaviour after liver transplantation
- Trial name
- NCT00170131
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Chronic HCV Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) in participants with advanced liver disease or posttransplant and chronic genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02010255
- Testing
- LDV/SOF, RBV
- Where
- 34 sites in Australia, Austria and 10 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Hepatitis C
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV…
- Trial name
- LADR (NCT00135798)
- Testing
- LADR Treatment
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Virus Infection, Liver Transplantation
Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation
Viral infections can profoundly influence alloimmune responses and hamper allograft tolerance induction. Persistent hepatitis C virus (HCV) infection occurs in 50% of liver and 20% of kidney transplant recipients, but the impact…
- Trial name
- NCT00668369
- Testing
- Gradual immunosuppression drug withdrawal.
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Hospital Clinic of Barcelona
Liver Transplantation
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
- Trial name
- NCT03133065
- Testing
- treatment of HCV with oral direct acting antiviral therapy
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Hepatitis C Virus
Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation
The purpose of this study is to learn about how different immunosuppressant therapies impact on recurrent hepatitis C virus infection in the new liver after liver transplant.
- Trial name
- NCT00710801
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Hepatitis C
Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation.
- Trial name
- NCT00383864
- Testing
- Pegylated interferon and ribavirin
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Hospital Clinic of Barcelona
Liver Transplant, Hepatitis C
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver.
- Trial name
- NCT00260208
- Testing
- Cyclosporine A, Tacrolimus
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 361 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Recurrence
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation
Recurrence of Hepatitis C virus infection (HCV) is universal after orthotopic liver transplantation (LTx) and is associated with allograft failure, death and need for re-transplantation.
- Trial name
- NCT01074203
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hepatitis C
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment.
- Trial name
- ALLY 1 (NCT02032875)
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Patients who are Hepatitis C Negative (HCV negative) and are on the waiting list for a lung transplant at NYULH who consent to participate in this study will receive a lung transplant from a deceased donor that is HCV positive.
- Trial name
- NCT03523871
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Chronic Hepatitis C Virus (HCV) Infection
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
The purpose of this study is to evaluate the effectiveness of telaprevir in combination with Peg-IFN-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis C virus (HCV) genotype 1.
- Trial name
- REPLACE (NCT01571583)
- Testing
- Telaprevir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria, Belgium and 4 more
- Volunteers
- 74 people
- Sponsor
- Janssen-Cilag International NV
Liver Transplantation
Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation
Background and Aim: The immunosuppression influence on the response to antiviral therapy (AVT) for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients remains controversial, especially for the rarely…
- Trial name
- NCT03665766
- Testing
- Cycloserine,Tacrolimus
- Volunteers
- 126 people
- Sponsor
- Ain Shams University